Datasheet for ABIN934803

HBSAg Protein (Subtype adr)

2 Publications

Go to Product page

Overview

Quantity:	1 mg
Target:	HBSAg (HBsAg)
Protein Characteristics:	Subtype adr
Origin:	Hepatitis B Virus (HBV)
Source:	Yeast
Protein Type:	Recombinant
Application:	ELISA

Product Details

Characteristics:	Purified recombinant HBsAg protein (Subtype adr) Expression System: Yeast
Purity:	> 95 % pure

Target Details

Target:	HBSAg (HBsAg)
Alternative Name:	HBsAg (HBsAg Products)
Target Type:	Viral Protein
Background:	HBsAg is the surface antigen of the Hepatitis-B-Virus (HBV). It indicates current Hepatitis B infection. Alternative Names: Hepatitis B Surface Antigen protein, Hepatitis B Surface Ag Subtype adr protein, Hepatitis B surface Ag protein

Application Details

Application Notes:	Each Investigator should determine their own optimal working dilution for specific applications.
Restrictions:	For Research Use only

Handling

Buffer:	10 mM PO4, 140 mM Sodium Chloride, pH 6.4 with 0.1 % NaN3.
Preservative:	Sodium azide
Precaution of Use:	WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
Handling Advice:	**Do not freeze.**
Storage:	4 °C
Storage Comment:	Store at 4 °C.

Publications

Product cited in:	Mehta, Cunningham, Flynn, Pepe, Obaro, Kapogiannis, Bethel, Luzuriaga: "Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination." in: **Vaccine**, Vol. 28, Issue 21, pp. 3672-8, (2010) (PubMed). Morrey, Bailey, Korba, Sidwell: "Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine." in: **Antiviral research**, Vol. 42, Issue 2, pp. 97-108, (1999) (PubMed).